Literature DB >> 26085151

Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.

Laura K Pritchard1, David J Harvey1, Camille Bonomelli1, Max Crispin2, Katie J Doores3.   

Abstract

UNLABELLED: The gp120/gp41 HIV-1 envelope glycoprotein (Env) is highly glycosylated, with up to 50% of its mass consisting of N-linked glycans. This dense carbohydrate coat has emerged as a promising vaccine target, with its glycans acting as epitopes for a number of potent and broadly neutralizing antibodies (bnAbs). Characterizing the glycan structures present on native HIV-1 Env is thus a critical goal for the design of Env immunogens. In this study, we used a complementary, multistep approach involving ion mobility mass spectrometry and high-performance liquid chromatography to comprehensively characterize the glycan structures present on HIV-1 gp120 produced in peripheral blood mononuclear cells (PBMCs). The capacity of different expression systems, including pseudoviral particles and recombinant cell surface trimers, to reproduce native-like glycosylation was then assessed. A population of oligomannose glycans on gp120 was reproduced across all expression systems, supporting this as an intrinsic property of Env that can be targeted for vaccine design. In contrast, Env produced in HEK 293T cells failed to accurately reproduce the highly processed complex-type glycan structures observed on PBMC-derived gp120, and in particular the precise linkage of sialic acid residues that cap these glycans. Finally, we show that unlike for gp120, the glycans decorating gp41 are mostly complex-type sugars, consistent with the glycan specificity of bnAbs that target this region. These findings provide insights into the glycosylation of native and recombinant HIV-1 Env and can be used to inform strategies for immunogen design and preparation. IMPORTANCE: Development of an HIV vaccine is desperately needed to control new infections, and elicitation of HIV bnAbs will likely be an important component of an effective vaccine. Increasingly, HIV bnAbs are being identified that bind to the N-linked glycans coating the HIV envelope glycoproteins gp120 and gp41, highlighting them as important targets for vaccine design. It is therefore important to characterize the glycan structures present on native, virion-associated gp120 and gp41 for development of vaccines that accurately mimic native-Env glycosylation. In this study, we used a number of analytical techniques to precisely study the structures of both the oligomannose and complex-type glycans present on native Env to provide a reference for determining the ability of potential HIV immunogens to accurately replicate the glycosylation pattern on these native structures.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26085151      PMCID: PMC4524065          DOI: 10.1128/JVI.01190-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

Review 1.  Evolutionary and immunological implications of contemporary HIV-1 variation.

Authors:  B Korber; B Gaschen; K Yusim; R Thakallapally; C Kesmir; V Detours
Journal:  Br Med Bull       Date:  2001       Impact factor: 4.291

2.  Frequent occurrence of pre-existing alpha 2-->8-linked disialic and oligosialic acids with chain lengths up to 7 Sia residues in mammalian brain glycoproteins. Prevalence revealed by highly sensitive chemical methods and anti-di-, oligo-, and poly-Sia antibodies specific for defined chain lengths.

Authors:  C Sato; H Fukuoka; K Ohta; T Matsuda; R Koshino; K Kobayashi; F A Troy; K Kitajima
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

3.  Fragmentation of negative ions from carbohydrates: part 2. Fragmentation of high-mannose N-linked glycans.

Authors:  David J Harvey
Journal:  J Am Soc Mass Spectrom       Date:  2005-05       Impact factor: 3.109

4.  Fragmentation of negative ions from carbohydrates: part 3. Fragmentation of hybrid and complex N-linked glycans.

Authors:  David J Harvey
Journal:  J Am Soc Mass Spectrom       Date:  2005-05       Impact factor: 3.109

5.  The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles.

Authors:  Carolina Herrera; Per Johan Klasse; Elizabeth Michael; Shivani Kake; Kelly Barnes; Christopher W Kibler; Lila Campbell-Gardener; Zhihai Si; Joseph Sodroski; John P Moore; Simon Beddows
Journal:  Virology       Date:  2005-07-20       Impact factor: 3.616

6.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

8.  Glycosylation site-specific analysis of clade C HIV-1 envelope proteins.

Authors:  Eden P Go; Qing Chang; Hua-Xin Liao; Laura L Sutherland; S Munir Alam; Barton F Haynes; Heather Desaire
Journal:  J Proteome Res       Date:  2009-09       Impact factor: 4.466

9.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

10.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

View more
  55 in total

1.  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

Authors:  Steven W de Taeye; Gabriel Ozorowski; Alba Torrents de la Peña; Miklos Guttman; Jean-Philippe Julien; Tom L G M van den Kerkhof; Judith A Burger; Laura K Pritchard; Pavel Pugach; Anila Yasmeen; Jordan Crampton; Joyce Hu; Ilja Bontjer; Jonathan L Torres; Heather Arendt; Joanne DeStefano; Wayne C Koff; Hanneke Schuitemaker; Dirk Eggink; Ben Berkhout; Hansi Dean; Celia LaBranche; Shane Crotty; Max Crispin; David C Montefiori; P J Klasse; Kelly K Lee; John P Moore; Ian A Wilson; Andrew B Ward; Rogier W Sanders
Journal:  Cell       Date:  2015-12-17       Impact factor: 41.582

2.  Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.

Authors:  Yu Liang; Miklos Guttman; James A Williams; Hans Verkerke; Daniel Alvarado; Shiu-Lok Hu; Kelly K Lee
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

3.  Structure and Immune Recognition of the HIV Glycan Shield.

Authors:  Max Crispin; Andrew B Ward; Ian A Wilson
Journal:  Annu Rev Biophys       Date:  2018-03-29       Impact factor: 12.981

Review 4.  Structural principles controlling HIV envelope glycosylation.

Authors:  Anna-Janina Behrens; Max Crispin
Journal:  Curr Opin Struct Biol       Date:  2017-03-29       Impact factor: 6.809

Review 5.  Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins.

Authors:  Yukako Ohyama; Kazuki Nakajima; Matthew B Renfrow; Jan Novak; Kazuo Takahashi
Journal:  Expert Rev Proteomics       Date:  2020-05-28       Impact factor: 3.940

6.  Native Conformation and Canonical Disulfide Bond Formation Are Interlinked Properties of HIV-1 Env Glycoproteins.

Authors:  Eden P Go; Albert Cupo; Rajesh Ringe; Pavel Pugach; John P Moore; Heather Desaire
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

Review 7.  Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1.

Authors:  Anna-Janina Behrens; Weston B Struwe; Max Crispin
Journal:  Expert Rev Proteomics       Date:  2017-09-14       Impact factor: 3.940

8.  Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.

Authors:  Shariq Mujib; Jun Liu; A K M Nur-Ur Rahman; Jordan A Schwartz; Phil Bonner; Feng Yun Yue; Mario A Ostrowski
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

9.  Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding.

Authors:  Yasunori Watanabe; Snezana Vasiljevic; Joel D Allen; Gemma E Seabright; Helen M E Duyvesteyn; Katie J Doores; Max Crispin; Weston B Struwe
Journal:  Anal Chem       Date:  2018-05-25       Impact factor: 6.986

10.  Travelling-wave ion mobility and negative ion fragmentation of high-mannose N-glycans.

Authors:  David J Harvey; Charlotte A Scarff; Matthew Edgeworth; Weston B Struwe; Kevin Pagel; Konstantinos Thalassinos; Max Crispin; Jim Scrivens
Journal:  J Mass Spectrom       Date:  2016-03       Impact factor: 1.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.